{"id":59797,"date":"2025-02-12T12:36:39","date_gmt":"2025-02-12T11:36:39","guid":{"rendered":"https:\/\/www.eurogroupconsulting.it\/?p=59797"},"modified":"2025-02-12T12:38:13","modified_gmt":"2025-02-12T11:38:13","slug":"omnichannel-marketing-mix-in-the-life-science-industry","status":"publish","type":"post","link":"https:\/\/www.eurogroupconsulting.it\/en\/omnichannel-marketing-mix","title":{"rendered":"Omnichannel Marketing Mix in the Life Science industry"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]<\/p>\n

Omnichannel Marketing Mix in the Life Science industry<\/strong><\/h3>\n

How to maximize stakeholders\u2019 engagement while optimizing investments in a multi-stakeholder \/ multi-touchpoint environment <\/em><\/h3>\n

[\/vc_column_text][vc_column_text css=””]The current global life science industry is characterized by great volatility<\/strong>, with a competitive landscape constantly evolving due to an increasing number of stakeholders in the customer journey<\/strong>, exploiting the newest channels and technologies<\/strong>. As a result, the vast amount of available information from a variety of alternative sources leads customers to continuously change their behavior and preferences<\/strong>.<\/p>\n

The customer journey has historically been influenced by multiple stakeholders such as physicians, pharmacists and consumers \/ patients; the weight that the single stakeholders have at each stage <\/strong>of the customer journey is drastically changing: from a single-stakeholder environment, primarily focused on physicians, to a multi-stakeholder environment, where other stakeholders are taking on an increasingly significant role and patients have access to wider knowledge through online research and peer comparisons.<\/p>\n

In this context, pharmaceutical companies are facing the challenge of moving away from a channel-based approach and siloed structures, <\/strong>where different internal functions work as totally separate departments, to an omnichannel mindset<\/strong> in which functions collaborate and contribute to a \u201cone-company\u201d approach<\/strong>.<\/p>\n

To thrive in this constantly evolving and fast-paced environment, companies must adapt and adjust their strategies<\/strong> as scenarios evolve. This requires exploring potential developments in the marketing mix<\/strong>, with a strong emphasis on digital assets<\/strong> and omnichannel initiatives<\/strong>.<\/p>\n

It is essential to understand that, especially in the life science industry, due to the extent and diversity of the available product portfolios, the optimal marketing mix can vary significantly not only between organizations but also across <\/strong>different<\/strong> business units within the same company<\/strong>, depending on the features of the products and the journey of the customers.<\/p>\n

A critical question therefore arises: How to maximize stakeholders\u2019 engagement through an effective marketing mix while optimizing investments<\/strong>?<\/em><\/p>\n

 <\/p>\n

To determine the optimal marketing mix, the following three-step approach can be adopted:[\/vc_column_text]